ArticleEuropean heart journal. Imaging methods and practice2025
Precision TAVR quantification- AI-accelerated TAVR planning reduces assessment time by 80% in bicuspid aortic stenosis.
Article in European heart journal. Imaging methods and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05044338 (China Degenerative Valve Disease II Cohort Study), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China Degenerative Valve Disease II Cohort Study (China-DVD2 Study)
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of left atrial function in cardiac amyloidosis: a systematic review and meta‑analysis.The international journal of cardiovascular imaging · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Bicuspid aortic valve (BAV) stenosis complicates transcatheter aortic valve replacement (TAVR) planning, with no validated automated measurement algorithm available. We developed Cardioverse, the first fully automated deep learning algorithm for BAV anatomical assessment in TAVR planning. Methods and results: We conducted a large-scale, multicenter retrospective study encompassing 1,147 consecutive patients with BAV undergoing TAVR across 16 high-volume Chinese centers (March 2019-February 2023). Cardioverse was trained on this cohort and evaluated in an internal ( Conclusion: Cardioverse transforms pre-TAVR assessment for BAV patients, offering a validated solution combining accuracy and efficiency. It reduces assessment time from over 20 min to < 5 min, addressing the need for standardized, rapid, and reliable BAV evaluation. Its robust performance across diverse BAV phenotypes makes it a crucial tool for enhancing TAVR planning consistency. Clinical trial registration: ClinicalTrials.gov Protocol Registration System (NCT05044338).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.